Myeloma News and Research

RSS
Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals initiates Phase 3 registration clinical trial for perifosine

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Initiation of multi-national Phase III study of Stimuvax announced

Initiation of multi-national Phase III study of Stimuvax announced

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

AHS annual meeting focuses on myeloma, says IMF

AHS annual meeting focuses on myeloma, says IMF

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presented

Scientists identify new potential drug for treating acute myeloid leukaemia

Scientists identify new potential drug for treating acute myeloid leukaemia

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

CombinatoRx presents encouraging results from its A2A and b2AR agonist programs for B-cell malignancies

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Encouraging results from Semafore Pharmaceuticals' SF1126 Phase I dose-escalation trial for myeloma

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Clinical trial results of VELCADE based combinations for MM to be presented at the ASH meeting

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Study data of REVLIMID-dexamethasone combination therapy for high-risk smoldering multiple myeloma

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Gentium presents evaluation results of Defibrotide for VOD at the ASH conference

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Study results comparing REVLIMID regimen to stem cell transplant in multiple myeloma patients

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

Study data of Perifosine + Bortezomib combination in multiple myeloma patients presented

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.